Psychiatr. praxi 2017; 18(2): 64-68 | DOI: 10.36290/psy.2017.012

Mirtazapine in clinical practice

MUDr. Sylva Racková, Ph.D.
1Psychiatrie, s. r. o., Plzeň
2Psychiatrická klinika VFN v Praze

Summary: Mirtazapine belongs to antidepressants with a dual mechanism of action (NaSSAs), influencing serotonergic and noradrenergic

neurotransmission. It is an antidepressant with a high efficacy in the treatment of depression. The efficacy of mirtazapine is comparable

with or higher than that of other antidepressants. It is different in the onset of action and in the profile of adverse events. The aim of this

article is to provide more information about this antidepressant and describe the type of patients who are suitable for this medication.

Keywords: mirtazapine, depression, meta-analysis, efficacy, sleep, sexual dysfunction

Published: July 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S. Mirtazapine in clinical practice. Psychiatr. praxi. 2017;18(2):64-68. doi: 10.36290/psy.2017.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anders M, Kitzlerová E. Mirtazapinum. Remedia 2004; 14(5): 386-397.
    2. Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord 2013; 15(5). Go to original source... Go to PubMed...
    3. Hirschfeld RMA. The use of mirtazapine in difficult-to-treat patient populations. Hum Psychopharmacol 2002; 17(suppl 1): S33-S36. Go to original source...
    4. Guelfi JD, Ansseau M, Timmerman L, K?rsgaard S; Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21(4): 425-431. Go to original source... Go to PubMed...
    5. Kim JE, Yoon SJ, Kim J, et al. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract 2011; 65(3): 323-329. Go to original source... Go to PubMed...
    6. Versiani M, Moreno R, Ramakers-van Moorsel CJA, et al. Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19(2): 137-146. Go to original source...
    7. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol 1998; 13(2): 63-73. Go to original source... Go to PubMed...
    8. Thase ME, Nierenberg AA, Keller MB, et al. Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 2001; 62(10): 782-788. Go to original source... Go to PubMed...
    9. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163(7): 1161-1172. Go to original source...
    10. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002; 51(2): 183-188. Go to original source...
    11. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008; 22(8): 843-848. Go to original source... Go to PubMed...
    12. Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010; 25(4): 189-198. Go to original source... Go to PubMed...
    13. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011; (12): CD006528. Go to original source...
    14. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA; MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24(1): 35-53. Go to original source...
    15. Khoo AL, Zhou HJ, Teng M, Lin L, Zhao YJ, Soh LB, Mok YM, Lim BP, Gwee KP. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs 2015; 29(8): 695-712. Go to original source...
    16. Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 2002; 17 Suppl 1: S27-32. Go to original source... Go to PubMed...
    17. Lavergne F, Berlin I, Gamma A, Stassen H, Angst J. Onset of improvement and response to mirtazapine in depression: a multicenter naturalistic study of 4771 patients. Neuropsychiatr Dis Treat 2005; 1(1): 59-68. Go to original source...
    18. Hashimoto T, Shiina A, Hasegawa T, Kimura H, Oda Y, Niitsu T, Ishikawa M, Tachibana M, Muneoka K, Matsuki S, Nakazato M, Iyo M. Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial. Ann Gen Psychiatry 2016; 15: 27. Go to original source... Go to PubMed...
    19. Alberti S, Chiesa A, Andrisano C, Serretti A. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. J Clin Psychopharmacol 2015; 35(3): 296-303. Go to original source... Go to PubMed...
    20. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25(6): 677-679. Go to original source... Go to PubMed...
    21. Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry 2012; 24(3): 215-224. Go to PubMed...
    22. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 Suppl 3: 10-21.
    23. Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014; 37(1): 19-31. Go to original source...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.